1. Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas.
- Author
-
Goncharov NV, Baklanov IN, Gulaia VS, Shuliak AP, Lanskikh DV, Zhmenia VM, Shmelev ME, Shved NA, Wu J, Liskovykh M, Larionov V, Kouprina N, and Kumeiko VV
- Subjects
- Humans, Cell Line, Tumor, Paclitaxel pharmacology, Paclitaxel therapeutic use, Mutation, Missense, CRISPR-Cas Systems genetics, Isocitrate Dehydrogenase genetics, Glioma genetics, Glioma pathology, Glioma drug therapy, Chromosomal Instability genetics, Brain Neoplasms genetics, Brain Neoplasms pathology, Brain Neoplasms drug therapy, Temozolomide therapeutic use, Temozolomide pharmacology, Tumor Suppressor Protein p53 genetics
- Abstract
Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP53 marker genes. While pathogenic variants of IDH1 and TP53 can be accompanied by chromosomal instability (CIN), the impact of IDH1 and TP53 mutations on genome stability remains unstudied. Elevated CIN might provide therapeutic targets, based on synergistic effects of chemotherapy with CIN-inducing drugs. Using an assay based on human artificial chromosomes, we investigated the impact of common glioma missense mutations in IDH1 and TP53 on chromosome transmission and demonstrated that IDH1R132H and TP53R248Q variants elevate CIN. We next found enhanced CIN levels and the sensitivity of IDH1
R132H/WT and TP53R248Q/R248Q genotypes, introduced into U87 MG glioma cells by CRISPR/Cas9, to different drugs, including conventional temozolomide. It was found that U87 MG cells carrying IDH1R132H/WT exhibit dramatic sensitivity to paclitaxel, which was independently confirmed on cell cultures derived from patients with naturally occurring IDH1R132H/WT . Overall, our results suggest that the development of CIN-enhancing therapy for glioma tumors with the IDH1R132H/WT genotype could be advantageous for adjuvant treatment., Competing Interests: None declared., (© The Author(s) 2025. Published by Oxford University Press on behalf of NAR Cancer.)- Published
- 2025
- Full Text
- View/download PDF